NI-2601

N/A

Report date: 2022/02/23 17:36:56

Base Information

Drug NameNI-2601

Drug Alias NameNI-2601

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers

TargetsCluster of differentiation 47Programmed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLight Chain Bioscience Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLight Chain Bioscience Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A